Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein

Simple item page
cg.authorship.typesCGIAR and developing country instituteen_US
cg.authorship.typesCGIAR and advanced research instituteen_US
cg.contributor.affiliationKenya Medical Research Instituteen_US
cg.contributor.affiliationUniversity of Oxforden_US
cg.contributor.affiliationLondon School of Hygiene and Tropical Medicineen_US
cg.contributor.affiliationInternational Livestock Research Instituteen_US
cg.contributor.crpAgriculture for Nutrition and Healthen_US
cg.contributor.donorWellcome Trusten_US
cg.contributor.donorOak Foundationen_US
cg.contributor.donorMedical Research Council, United Kingdomen_US
cg.coverage.countryKenyaen_US
cg.coverage.iso3166-alpha2KEen_US
cg.coverage.regionAfricaen_US
cg.coverage.regionEastern Africaen_US
cg.creator.identifierBernard Bett: 0000-0001-9376-2941en_US
cg.howPublishedFormally Publisheden_US
cg.identifier.doihttps://doi.org/10.1016/j.isci.2020.101669en_US
cg.isijournalISI Journalen_US
cg.issn2589-0042en_US
cg.issue11en_US
cg.journaliScienceen_US
cg.reviewStatusPeer Reviewen_US
cg.subject.ilriANIMAL DISEASESen_US
cg.subject.ilriEPIDEMIOLOGYen_US
cg.subject.ilriHUMAN HEALTHen_US
cg.subject.ilriRVFen_US
cg.volume23en_US
dc.contributor.authorWright, D.en_US
dc.contributor.authorAllen, E.R.en_US
dc.contributor.authorClark, M.H.A.en_US
dc.contributor.authorGitonga, J.N.en_US
dc.contributor.authorKaranja, H.K.en_US
dc.contributor.authorHulswit, R.J.G.en_US
dc.contributor.authorTaylor, I.en_US
dc.contributor.authorBiswas, S.en_US
dc.contributor.authorMarshall, J.en_US
dc.contributor.authorMwololo, D.en_US
dc.contributor.authorMuriuki, J.en_US
dc.contributor.authorBett, Bernard K.en_US
dc.contributor.authorBowden, T.A.en_US
dc.contributor.authorWarimwe, G.M.en_US
dc.date.accessioned2020-10-26T13:06:12Zen_US
dc.date.available2020-10-26T13:06:12Zen_US
dc.identifier.urihttps://hdl.handle.net/10568/109976en_US
dc.titleNaturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoproteinen_US
dcterms.abstractRift Valley fever (RVF) is a viral hemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following RVF virus (RVFV) infection and that this correlates with acquisition of virus-neutralizing antibodies (nAbs) that target the viral envelope glycoproteins. However, naturally acquired immunity to RVF in humans is poorly described. Here, we characterized the immune response to the viral envelope glycoproteins, Gn and Gc, in RVFV-exposed Kenyan adults. Long-lived IgG (dominated by IgG1 subclass) and T cell responses were detected against both Gn and Gc. However, antigen-specific antibody depletion experiments showed that Gn-specific antibodies dominate the RVFV nAb response. IgG avidity against Gn, but not Gc, correlated with nAb titers. These data are consistent with the greater level of immune accessibility of Gn on the viral envelope surface and confirm the importance of Gn as an integral component for RVF vaccine development.en_US
dcterms.accessRightsOpen Accessen_US
dcterms.audienceScientistsen_US
dcterms.bibliographicCitationWright, D., Allen, E.R., Clark, M.H.A., Gitonga, J.N., Karanja, H.K., Hulswit, R.J.G., Taylor, I., Biswas, S., Marshall, J., Mwololo, D., Muriuki, J., Bett, B., Bowden, T.A. and Warimwe, G.M. 2020. Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein. iScience 23(11): 101669.en_US
dcterms.issued2020-11en_US
dcterms.languageenen_US
dcterms.licenseCC-BY-NC-ND-4.0en_US
dcterms.publisherElsevieren_US
dcterms.subjectimmunologyen_US
dcterms.subjectvirologyen_US
dcterms.subjectrift valley fever virusen_US
dcterms.typeJournal Articleen_US

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ILRI articles in journals
CRP A4NH outputs
ILRI animal and human health program outputs (2017-2024)